Lymphoplasmacytic lymphoma with biclonal M protein: report of one case and review of literature

VernacularTitle:伴双克隆M蛋白的淋巴浆细胞淋巴瘤一例并文献复习
Author: Jingjing JIANG ¹ ; Guangyu QI ; Meiling ZHOU ; Jinbo LU ; Yongfen HUANG ; Lingling WANG ; Hao XU ; Yuexin CHENG
Author Information

1. 江苏省盐城市第一人民医院　徐州医科大学附属盐城医院　南通大学第四附属医院血液内科　224006
From: Journal of Leukemia & Lymphoma 2020;29(5):291-294
CountryChina
Language:Chinese
Abstract: Objective:To investigate the clinical features, diagnosis and treatment of lymphoplasmacytic lymphoma (LPL) with biclonal M protein.Methods:The clinical data of one LPL patient with biclonal M protein at Yancheng First People's Hospital in January 2018 was retrospectively analyzed, and relevant literature was reviewed.Results:The patient was an elderly woman with clinical manifestations of lymphadenopathy, kidney damage, anemia, and bone destruction. The diagnosis was confirmed based on lymph node biopsy, immunofixation electrophoresis, bone marrow cytology, and genetic mutation testing (MYD88 L265P mutation-positive). Partial remission was achieved after 4 courses of treatment with bortezomib-based regimen.Conclusions:Clinically, LPL with biclonal M protein shows one characteristic of M protein, and the immunoglobulin IgM and IgA biclonal LPL is even rarer. The treatment scheme based on bortezomib has a certain therapeutic effect.